Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the effects of amlodipine alone versus amlodipine combined with folic acid in Chinese adults aged 45 to 74 years who have H-type hypertension, specific MTHFR 677 genotypes CC or CT, elevated plasma homocysteine levels, and low serum folate. This large, multi-center, randomized, double-blind, double-dummy clinical trial aims to evaluate which treatment better reduces the risk of first ischemic stroke over five years. Participants are first screened and then enter a 2 to 4 week run-in period where they take amlodipine to assess tolerance and compliance. Afterward, eligible participants are randomized by genotype into two groups one receiving amlodipine 5mg daily with a placebo, and the other receiving amlodipine 5mg combined with 0.8mg folic acid daily with a placebo. Other blood pressure medications may be added as needed to reach target blood pressure goals. Follow-up visits occur every three months during the five-year treatment period with medication provided at each visit. Throughout the study, participants undergo interviews, clinical evaluations, and laboratory tests including genetic and blood analyses. Researchers monitor adherence, blood pressure, and cardiovascular health. The main outcome measured is the occurrence of first ischemic stroke by the end of five years. Secondary outcomes include other cardiovascular events and kidney function. Two interim analyses will be conducted during the study to assess progress and safety.
Actively Recruiting
Researchers are evaluating the effects of different amlodipine-based treatments on the risk of first ischemic stroke in Chinese adults aged 45 to 74 years with hypertension and the MTHFR 677 TT genotype. This large, multi-center, randomized, double-blind, triple-dummy controlled trial aims to compare amlodipine alone, amlodipine combined with folic acid, and amlodipine combined with folic acid plus 5-methyltetrahydrofolate over a 5-year period. The study focuses on preventing ischemic stroke as the primary outcome. Participants first undergo a screening period to confirm eligibility through interviews, clinical evaluations, and lab tests. Those who qualify enter a 2 to 4 week run-in phase with daily amlodipine to check treatment tolerance and compliance. Eligible participants are then randomly assigned to one of three daily oral treatment groups amlodipine alone, amlodipine folic acid, or amlodipine folic acid plus 5-MTHF. Additional antihypertensive medications may be added as needed to control blood pressure. Participants are followed every 3 months for drug distribution and monitoring. Throughout the study, participants will have regular clinical visits, interviews, and biological sample collections to monitor health and treatment effects. Researchers will track the incidence of first ischemic stroke and other cardiovascular and kidney outcomes over five years. Safety and treatment adherence are carefully observed, with two planned interim analyses during the trial. Total participation spans from initial screening through five years of treatment and follow-up.
Actively Recruiting
Researchers are evaluating the use of oral Vonoprazan, a potassium-competitive acid blocker, compared to standard high dose proton pump inhibitor PPI therapy for patients with bleeding peptic ulcers who have received successful endoscopic haemostasis. This multicenter randomized controlled trial aims to determine whether Vonoprazan is not worse than the standard intravenous PPI infusion at preventing recurrent bleeding within 30 days. Upper gastrointestinal bleeding remains a serious condition, and effective acid suppression helps stabilize clots and prevent further bleeding. Participants will be randomly assigned to receive either a high dose PPI infusion consisting of an 80mg intravenous bolus of esomeprazole followed by continuous infusion at 8mg per hour for 72 hours, or oral Vonoprazan at 40mg twice daily for 72 hours followed by 20mg daily from day 4 to day 30. The study compares these two acid suppression methods after endoscopic treatment to assess their effects on recurrent bleeding and related outcomes. During the study, participants will be monitored for recurrent bleeding, need for additional hemostatic treatment, and length of hospital and intensive care stay within 30 days after randomization. Researchers will also investigate Vonoprazans effect on intragastric pH in this clinical setting. The total participation time includes treatment and follow-up assessments extending to 30 days after starting the assigned therapy.
Actively Recruiting
Researchers are evaluating the use of manual thrombus aspiration during primary percutaneous coronary intervention PCI in patients who have suffered a ST-segment Elevation Myocardial Infarction STEMI and have a high thrombus burden, defined as TIMI thrombus grade 3 or higher. This study aims to determine whether thrombus aspiration can reduce major cardiovascular events such as cardiovascular death, recurrent heart attacks, stent thrombosis, target vessel revascularization within 180 days, or stroke within 30 days after the procedure. Participants are randomly assigned in equal numbers to one of two groups one group receives upfront manual thrombus aspiration followed by PCI, while the other group undergoes PCI without thrombus aspiration. The procedures are performed within 12 hours of symptom onset. This open-label, multicenter trial compares the outcomes of these two approaches to better understand the potential benefits and risks of thrombus aspiration in this patient population. During the study, participants will be closely monitored for major adverse cardiovascular events up to 180 days after treatment, with additional assessments for stroke within 30 days and composite cardiocerebrovascular events up to one year. Researchers will collect clinical data to evaluate the effectiveness of the treatments. The total duration of participation includes these follow-up periods, ensuring thorough observation of safety and outcomes after the initial intervention.